Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 6/20 | 0.40 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | CPA1 | P15085 | 1/20 | 0.36 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4989841 | 0.86 | DPP4 (0.40) | MMEDPP4AKR1C3AKR1C2PTGS1 | |
| SCHEMBL3995695 | 0.84 | GRIK1 (0.39) | MMEDPP4AKR1C3AKR1C2PTGS1 | |
| SCHEMBL4001272 | 0.84 | GRIK1 (0.39) | MMEDPP4AKR1C3AKR1C2PTGS1 | |
| SCHEMBL3994836 | 0.84 | GRIK1 (0.39) | MMEDPP4AKR1C3AKR1C2PTGS1 | |
| SCHEMBL4989923 | 0.84 | MME (0.43) | MMEAKR1C3ACECPA1PTGS1 | |
| SCHEMBL4988034 | 0.84 | MME (0.39) | MMEDPP4DPP7ACECPA1 | |
| SCHEMBL4992791 | 0.82 | SLC1A1 (0.53) | — | |
| SCHEMBL4985963 | 0.82 | PSMB8 (0.40) | ACE | |
| SCHEMBL4990094 | 0.82 | ALOX15 (0.55) | MMEACEPTGS1PTGS2 | |
| SCHEMBL4989888 | 0.81 | SLC1A1 (0.35) | MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1667957-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA-PROTEIN | Warner-Lambert Company LLC (US) | 2006-06-14 | — | — | EP | claimed |
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | claimed |
| WO-2005030700-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA-PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2005-04-07 | — | — | WO | claimed |
| US-7388023-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2008-06-17 | — | — | US | disclosed |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WANER-LAMBERT COMPANY LLC (US) | 2007-06-07 | — | — | US | disclosed |
| US-7179934-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2007-02-20 | — | — | US | disclosed |
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | disclosed |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, SCN1A, OPRD1 | MME 2393/4885DPP4 2680/4885DPP7 1811/4885 |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | SCN2A, OPRD1, SCN1A | MME 2286/4885DPP4 3263/4885DPP7 2158/4885 |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | MME 2084/4885DPP4 2672/4885DPP7 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.